zealand pharma obesity

Roche, obesity and Zealand Pharma

Roche secures Zealand obesity drug candidate for up to $5.3 billion

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss drugmaker seeks to boost its prospects in the booming weight-loss market.

CNBC on MSN · 2d

Roche shares pop 4% on $5.3 billion obesity drug deal with Zealand Pharma

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand Pharma's obesity drug candidate.

Seeking Alpha on MSN · 2d

Roche, Zealand Pharma enter $5.3B license deal for obesity treatment

Roche (OTCQX:RHHBY) is looking to boost its presence in the booming weight-loss market through an exclusive collaboration and licensing deal with Danish biotech Zealand Pharma (OTCPK:ZLDPF). Under the terms of deal,

Medical Dialogues23h

Roche, Zealand Pharma ink pact to co-develop, co-commercialise petrelintide as foundational therapy for obesity

Basel: Roche has announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma.

Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update

NVO reports disappointing data from a phase III study on a novel obesity candidate, CagriSema. RHHBY buys rights to obesity candidate from Zealand Pharma.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Roche, obesity and Zealand Pharma

Trending now